In vivo imaging of the integration and function of nigral grafts in clinical trials

Progress in Brain Research

Volumn 200, Issue , 2012, Pages 199-220

  Politis, Marios ^a   Piccini, Paola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

MRI; Neural grafts; Parkinson's disease; PET; SPECT

Indexed keywords

ALTROPANE I 123; AMPHETAMINE; APOMORPHINE; DOPAMINE; LEVODOPA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A AGONIST; SETOPERONE F 18; UNCLASSIFIED DRUG; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M;

ANTERIOR CINGULATE; ARTICLE; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN GRAFT; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; DOPAMINE RELEASE; DYSKINESIA; FETAL STEM CELL; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; GRAFT INDUCED DYSKINESIA; HUMAN; IMAGING; IMMUNE RESPONSE; IN VIVO STUDY; MOVEMENT (PHYSIOLOGY); NERVE GRAFT; NEUROIMAGING; PARKINSON DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; POSTERIOR PARIETAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; SENSORIMOTOR CORTEX; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SUPPLEMENTARY MOTOR AREA; THALAMUS;

EID: 84870260355     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59575-1.00009-0     Document Type: Chapter

References (93)

1. Ballanger B., Strafella A.P., van Eimeren T., Zurowski M., Rusjan P.M., Houle S., Fox S.H. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch. Neurol. 2010, 67:416-421.
2. Bartzokis G., Cumming J.L., Markham C.H., Marmarelis P.Z., Treciokas L.J., Tishler T.A., Marder S.R., Mintz J. MRI evaluation of brain iron earlier and later onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 1999, 17:213-222.
3. Basser P.J., Mattiello J., LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys. J. 1994, 66:259-267.
4. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., Kupsch A., Crabb L., Odin P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Oertel W.H., Quinn N.P., Rehncrona S., Lindvall O. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123:1380-1390.
6. Bullmore E., Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat. Rev. Neurosci. 2009, 10:186-198.
7. Ceballos-Baumann A.O., Boecker H., Bartenstein P., von Falkenhayn I., Riescher H., Conrad B., Moringlane J.R., Alesch F. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch. Neurol. 1999, 56:997-1003.
8. Ciccarelli O., Catani M., Johansen-Berg H., Clark C., Thompson A. Diffusion-based tractography in neurological disorders: concepts, applications, and future developments. Lancet Neurol. 2008, 7:715-727.
9. Cochen V., Ribeiro M.J., Nguyen J.P., Gurruchaga J.M., Villafane G., Loc'h C., Defer G., Samson Y., Peschanski M., Hantraye P., Cesaro P., Remy P. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Mov. Disord. 2003, 18:928-932.
10. de la Fuente-Fernández R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., Lee C.S., Ruth T.J., Calne D.B., Stoessl A.J. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 2001, 49:298-303.
11. Delaville C., Deurwaerdère P.D., Benazzouz A. Noradrenaline and Parkinson's disease. Front. Syst. Neurosci. 2011, 5:31.
12. Dexter D.T., Sian J., Jenner P., Marsden C.D. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 1993, 60:273-281.
13. Du G., Lewis M.M., Styner M., Shaffer M.L., Sen S., Yang Q.X., Huang X. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov. Disord. 2011, 26:1627-1632.
14. Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E.S. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J. Neurochem. 1987, 48:1077-1082.
15. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., Lone T., Zhang Y.B., Snyder J.A., Wells T.H. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 1992, 327:1549-1555.
16. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
17. Freeman T.B., Olanow C.W., Hauser R.A., Nauert G.M., Smith D.A., Borlongan C.V., Sanberg P.R., Holt D.A., Kordower J.H., Vingerhoets F.J. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 1995, 38:379-388.
18. Fukuda M., Mentis M., Ghilardi M.F., Dhawan V., Antonini A., Hammerstad J., Lozano A.M., Lang A., Lyons K., Koller W., Ghez C., Eidelberg D. Functional correlates of pallidal stimulation for Parkinson's disease. Ann. Neurol. 2001, 49:155-164.
19. Greicius M. Resting-state functional connectivity in neuropsychiatric disorders. Curr. Opin. Neurol. 2008, 21:424-430.
20. Gupta D., Saini J., Kesavadas C., Sarma P.S., Kishore A. Utility of susceptibility-weighted MRI in differentiating Parkinson's disease and atypical parkinsonism. Neuroradiology 2010, 52:1087-1094.
21. Guye M., Bartolomei F., Ranjeva J.P. Imaging structural and functional connectivity: towards a unified definition of human brain organization?. Curr. Opin. Neurol. 2008, 21:393-403.
22. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res. Bull. 2005, 68:4-15.
23. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Quinn N.P., Lindvall O. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain 1999, 122:1121-1132.
24. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., Crabb L., Pavese N., Oertel W.H., Quinn N., Brooks D.J., Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
25. Haslinger B., Erhard P., Kämpfe N., Boecker H., Rummeny E., Schwaiger M., Conrad B., Ceballos-Baumann A.O. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001, 124:558-570.
26. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 1999, 56:179-187.
27. Isacson O., Björklund L.M., Schumacher J.M. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann. Neurol. 2003, 53:S135-S148.
28. Jahanshahi M., Jenkins I.H., Brown R.G., Marsden C.D., Passingham R.E., Brooks D.J. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 1995, 118:913-933.
29. Jenkins I.H., Fernandez W., Playford E.D., Lees A.J., Frackowiak R.S., Passingham R.E., Brooks D.J. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann. Neurol. 1992, 32:749-757.
30. Kish S.J. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?. Adv. Neurol. 2003, 91:39-49.
31. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
32. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sanberg P.R., Hauser R.A., Smith D.A., Nauert G.M., Perl D.P. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 1995, 332:1118-1124.
33. Kordower J.H., Freeman T.B., Chen E.Y., Mufson E.J., Sanberg P.R., Hauser R.A., Snow B., Olanow C.W. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov. Disord. 1998, 13:383-393.
34. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
35. Kuhn D.M., Sykes C.E., Geddes T.J., Jaunarajs K.L., Bishop C. Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. J. Neurochem. 2011, 116:426-437.
36. Li J.Y., Englund E., Holton J.L., Soulet D., Hagell P., Lees A.J., Lashley T., Quinn N.P., Rehncrona S., Björklund A., Widner H., Revesz T., Lindvall O., Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
37. Lindvall O., Björklund A. Cell therapeutics in Parkinson's disease. Neurotherapeutics 2011, 8:539-548.
38. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K.L., Sawle G., Rothwell J.C., Marsden C.D. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 4942:574-577.
39. Lindvall O., Sawle G., Widner H., Rothwell J.C., Björklund A., Brooks D., Brundin P., Frackowiak R., Marsden C.D., Odin P. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 1994, 35:172-180.
40. Loane C., Politis M. Positron emission tomography neuroimaging in Parkinson's disease. Am. J. Transl. Res. 2011, 3:323-341.
41. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., Breeze R., Fahn S., Freed C., Eidelberg D. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann. Neurol. 2002, 52:628-634.
42. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J. Nucl. Med. 2010, 51:7-15.
43. Mendez I., Dagher A., Hong M., Gaudet P., Weerasinghe S., McAlister V., King D., Desrosiers J., Darvesh S., Acorn T., Robertson H. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J. Neurosurg. 2002, 96:589-596.
44. Mendez I., Viñuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., Tierney T., Holness R., Dagher A., Trojanowski J.Q., Isacson O. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
45. Mori S., Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006, 51:527-539.
46. Morris E.D., Fisher R.E., Alpert N.M., Rauch S.L., Fischman A.J. In vivo imaging of neuromodulation using positron emission tomography: optimal ligand characteristics and task length for detection of activation. Hum. Brain Mapp. 1995, 3:35-55.
47. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
48. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry 1998, 64:314-319.
49. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
50. O'Sullivan S.S., Wu K., Politis M., Lawrence A.D., Evans A.H., Bose S.K., Djamshidian A., Lees A.J., Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011, 134:969-978.
51. Pavese N., Metta V., Bose S.K., Chaudhuri K.R., Brooks D.J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133:3434-3443.
52. Péran P., Cherubini A., Assogna F., Piras F., Quattrocchi C., Peppe A., Celsis P., Rascol O., Démonet J.F., Stefani A., Pierantozzi M., Pontieri F.E., Caltagirone C., Spalletta G., Sabatini U. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010, 133:3423-3433.
53. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., Geny C., Samson Y., Hantraye P., Jeny R., Gaston A., Keravel Y., Degos J.D., Cesaro P. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994, 117:487-499.
54. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., Lindvall O. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
55. Piccini P., Lindvall O., Björklund A., Brundin P., Hagell P., Ceravolo R., Oertel W., Quinn N., Samuel M., Rehncrona S., Widner H., Brooks D.J. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 2000, 48:689-695.
56. Piccini P., Pavese N., Brooks D.J. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann. Neurol. 2003, 53:647-653.
57. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., Quinn N.P., Brooks D.J., Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
58. Playford E.D., Jenkins I.H., Passingham R.E., Nutt J., Frackowiak R.S., Brooks D.J. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann. Neurol. 1992, 32:151-161.
59. Pogarell O., Koch W., Gildehaus F.J., Kupsch A., Lindvall O., Oertel W.H., Tatsch K. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:407-411.
60. Politis M. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. BMC Med. 2010, 8:80.
61. Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Med. 2011, 9:50.
62. Politis M., Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012, 10:1.
63. Politis M., Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. Scientific World Journal 2011, 11:1726-1734.
64. Politis M., Piccini P. Brain imaging after neural transplantation. Prog. Brain Res. 2010, 184:193-203.
65. Politis M., Piccini P. Positron emission tomography imaging in neurological disorders. J. Neurol. 2012, 259:1769-1780.
66. Politis M., Piccini P., Pavese N., Koh S.B., Brooks D.J. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp. Neurol. 2008, 214:112-116.
67. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Björklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
68. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-221.
69. Politis M., Wu K., Molloy S.G., Bain P., Chaudhuri K.R., Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov. Disord. 2010, 25:1646-1651.
70. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphé and limbic structures. Neurology 2010, 75:1920-1927.
71. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., Björklund A., Lindvall O., Piccini P. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
72. Politis M., Loane C., Wu K., Brooks D.J., Piccini P. Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol. Dis. 2011, 43:609-615.
73. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., Björklund A., Lindvall O., Piccini P. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci. Transl. Med. 2012, 4:128ra41.
74. Politis M., Su P., Piccini P. Imaging of microglia in patients with neurodegenerative disorders. Front. Neuropharm. 2012, 3:96.
75. Rascol O., Sabatini U., Chollet F., Fabre N., Senard J.M., Montastruc J.L., Celsis P., Marc-Vergnes J.P., Rascol A. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J. Neurol. Neurosurg. Psychiatry 1994, 57:567-571.
76. Remy P., Samson Y., Hantraye P., Fontaine A., Defer G., Mangin J.F., Fénelon G., Gény C., Ricolfi F., Frouin V. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann. Neurol. 1995, 38:580-588.
77. Rolheiser T.M., Fulton H.G., Good K.P., Fisk J.D., McKelvey J.R., Scherfler C., Khan N.M., Leslie R.A., Robertson H.A. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. J. Neurol. 2011, 258:1254-1260.
78. Rowe J., Stephan K.E., Friston K., Frackowiak R., Lees A., Passingham R. Attention to action in Parkinsons disease: impaired effective connectivity among frontal cortical regions. Brain 2002, 125:276-289.
79. Sawle G.V., Bloomfield P.M., Björklund A., Brooks D.J., Brundin P., Leenders K.L., Lindvall O., Marsden C.D., Rehncrona S., Widner H. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann. Neurol. 1992, 31:166-173.
80. Skidmore F.M., Yang M., Baxter L., von Deneen K.M., Collingwood J., He G., White K., Korenkevych D., Savenkov A., Heilman K.M., Gold M., Liu Y. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage 2011, (Epub ahead of print).
81. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 1993, 34:324-330.
82. Sullivan A.M., Pohl J., Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. Eur. J. Neurosci. 1998, 10:3681-3688.
83. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., Weinshenker D., Greene J.G., Miller G.W. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 2009, 29:8103-8113.
84. Tessa C., Lucetti C., Diciotti S., Paoli L., Cecchi P., Giannelli M., Baldacci F., Ginestroni A., Vignali C., Mascalchi M., Bonuccelli U. Hypoactivation of the primary sensorimotor cortex in de novo Parkinson's disease: a motor fMRI study under controlled conditions. Neuroradiology 2012, 54:261-268.
85. Vaillancourt D.E., Spraker M.B., Prodoehl J., Abraham I., Corcos D.M., Zhou X.J., Comella C.L., Little D.M. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009, 72:1378-1384.
86. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Schlyer D., Hitzemann R., Lieberman J., Angrist B., Pappas N., MacGregor R. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994, 16:255-262.
87. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Brown R., Gustavii B., Hagell P., Jahanshahi M., Sawle G., Björklund A., Brooks D.J., Marsden C.D., Quinn N.P., Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann. Neurol. 1997, 42:95-107.
88. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Björklund A., Lindvall O., Langston J.W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 1992, 327:1556-1563.
89. Wood L.D., Neumiller J.J., Setter S.M., Dobbins E.K. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. Am. J. Geriatr. Pharmacother. 2010, 8:294-315.
90. Wu T., Long X., Zang Y., Wang L., Hallett M., Li K., Chan P. Regional homogeneity changes in patients with Parkinson's disease. Hum. Brain Mapp. 2009, 30:1502-1510.
91. Wu K., Politis M., Piccini P. Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad. Med. J. 2009, 85:590-596.
92. Wu T., Long X., Wang L., Hallett M., Zang Y., Li K., Chan P. Functional connectivity of cortical motor areas in the resting state in Parkinson's disease. Hum. Brain Mapp. 2011, 32:1443-1457.
93. Zhang J., Zhang Y., Wang J., Cai P., Luo C., Qian Z., Dai Y., Feng H. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res. 2010, 1330:124-130.